Biotechnology

Scaling Cryopreservation with Until Co-Founder and CEO Laura Deming

Scaling Cryopreservation with Until Co-Founder and CEO Laura Deming

Laura Deming, co-founder and CEO of Until, discusses the ambitious goal of making reversible cryopreservation a reality. She outlines the company's vision, starting with preserving human organs to revolutionize transplantation and progressing towards whole-body medical hibernation, allowing patients to "pause" biological time and await future cures. The conversation delves into the core scientific challenges, reframing cryopreservation as an engineering problem of heat transfer and managing ice formation, and explores why this promising field has been historically underfunded.

The Brutal Truth About Biotech: Why $2B Per Drug Is Killing Innovation

The Brutal Truth About Biotech: Why $2B Per Drug Is Killing Innovation

Venture capitalists Elliot Hershberg and Lada Nuzhna analyze the structural crises facing the biotech industry, from Eroom's Law driving drug development costs to $2.5 billion, to China's rapid, low-cost clinical trials outmaneuvering US startups. They argue that for American biotech to survive, it must shift from competing on commoditized platforms to inventing entirely new modalities and medicines that are impossible to create without bleeding-edge tools like AI, targeting massive opportunities like aging.